SUSIANTO, INDRA ADI and Mandagie, Aprilia Karen and KRISTANTI, ALBERTA WIDYA and Hartono, Edward and HARDIMARTA, FRANSISCA Effects of andrographolide on p53 and Ki67 expression in an experimental mouse model of endometriosis. Journal of Advanced Biotechnology and Experimental Therapeutics, 9 (3). pp. 613-622. ISSN 2616-4760

Preview	Text jabet scopus Q3.pdf Download (876kB) | Preview
Preview	Text KORESPONDENSI KABET SCOPUS Q3.pdf Download (1MB) | Preview
Preview	Text trunitiy scopus q3 jabet.pdf Download (1MB) | Preview
Preview	Text EC dr Indra Adi Susianto20241106_0531.pdf Download (115kB) | Preview

Abstract

ndometriosis is a long-term condition that causes inflammation and leads to the growth of abnormal tissue outside the uterus. This tissue can cause significant problems, including pain and infertility. Researchers have been seeking new ways to treat endometriosis, and one promising treatment option is andrographolide. This compound comes from a plant called Andrographis paniculata and has been shown to stop the growth of abnormal cells and promote cell death. To learn more about how andrographolide works, the current study conducted an experiment using mice with endometriosis. The mice were divided into six groups: a normal group, an endometriosis group that didn't receive any treatment, a group that received a standard treatment, and three groups that received different doses of andrographolide. Tissue samples from each group were examined to see how the treatment affected the growth of abnormal cells. The mice that received andrographolide had lower levels of certain proteins, such as p53 and Ki67, which are associated with cell growth and division, respectively. Andrographolide might be able to slow down the growth of abnormal tissue in endometriosis. However, the differences between the andrographolide groups and the standard treatment group were not statistically significant. Despite this, the study suggests that andrographolide might be a useful treatment for endometriosis, particularly for women who prefer not to use hormonal therapies. More research is needed to determine the optimal dose and treatment schedule, but the results are promising. The fact that andrographolide appears to target specific molecular markers associated with endometriosis makes it a potentially powerful tool for treating this condition. With further development, andrographolide could become a valuable treatment option available to women with endometriosis.

Actions (login required)

View Item